| Autor: |
Lili Zhan, Xinjian Cai, Yanan Zhang |
| Předmět: |
|
| Zdroj: |
Clinical Laboratory; 2024, Vol. 70 Issue 1, p179-182, 4p |
| Abstrakt: |
Background: Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor originating from the epithelium of the pancreatic duct. Neoadjuvant chemotherapy FOLFIRINOX (a combination of oxaliplatin, irinotecan, and 5- fluorouracil/leucovorin) is considered to be the most effective regimen for patients with resected pancreatic cancer. Methods: This article reports a case of a pancreatic ductal adenocarcinoma patient who exhibited regular periodic fluctuations in the serum iron level during FOLFIRINOX. Results: It indicates that an unexplained increase in serum iron levels after each cycle of FOLFIRINOX is non-cell destructive and due to a reduction in iron consumption, after ruling out other potential causes. Conclusions: FOLFIRINOX in pancreatic cancer patients may cause an elevation of serum iron levels. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
